Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens (2Gether)

26 de noviembre de 2018 actualizado por: Centers for Disease Control and Prevention

This trial will evaluate a multi-component, clinic-based intervention aimed at increasing dual protection strategy selection and adherence among young African American females at an urban family planning clinic. Dual protection is the use of contraceptive strategies to prevent both unintended pregnancy (UIP) and sexually transmitted infections (STIs). This is an unblinded randomized controlled trial; participants will either get the interactive multimedia platform focused on DP strategies with intervention arm counseling or the standard of care arm counseling.

The study will recruit 710 African American females aged 14-19 who are attending the Grady Health System (GHS) Teen Services Clinic (TSC) in Atlanta, Georgia, for reproductive health care.

The trial will recruit and enroll 710 young women presenting to the clinic for clinical care who have the following characteristics:

  • self-identify as African American,
  • 14-19 years of age,
  • have had vaginal sex with a male partner in the past 6 months,
  • HIV-negative by self-report,
  • not pregnant,verified by urine pregnancy test,
  • no desire to be pregnant in next 12 months,
  • plan to stay in the Atlanta area for the next year,
  • are willing to provide contact information, and
  • were not previously enrolled in the pilot study of this intervention.

Those enrolled will be in the study for 12 months. Young women who are eligible and give written consent or assent for study participation will be enrolled. Half will be randomized to the control arm, half to the intervention arm.

  1. Control arm (standard of care) includes individual clinical care and standard of care counseling consistent with protocols at the TSC, with study visits for data collection at enrollment, 6 months, and 12 months, during which any medical care or counseling that they would normally get will also be provided. Control arm participants will also get telephone calls from clinic staff to update their contact information and remind them of upcoming visits at 3 weeks and 5 months after the enrollment visit, and at 3 weeks and 5 months after the 6 month visit.
  2. Intervention arm, consisting of the following intervention components:

    1. Enrollment visit

      • A culturally-appropriate interactive multimedia platform focused on DP strategies and designed to prepare the individual for selection of a DP strategy.
      • Individual intervention arm counseling to select the DP strategy that is best suited for the participant (by a clinic health care provider).
      • Individual intervention arm counseling to build skills for correct and consistent use of the selected DP strategy (by a nurse educator (NE)).
    2. Booster counseling via phone at about 3 weeks and 5 months after the enrollment visit, and at about 3 weeks and 5 months after the 6 month visit (by an NE).
    3. 6 month visit

      • An abbreviated version of the interactive multimedia platform focused on dual protection strategies and strategy adherence.
      • Individual intervention arm counseling to reinforce skills for correct and consistent use of the DP strategy (by an NE).

At the final study visit at 12 months there is no difference between the counseling provided to the two groups; participants in both arms will receive the clinic standard of care.

Participants in both arms of the study will follow the same data collection procedures throughout the study:

  • At all three study visits, participants in both arms will receive urine pregnancy and STI tests and complete an audio computer assisted self-interview (ACASI) questionnaire.
  • At 3 and 9 months after enrollment, participants in both arms will receive a data collection call with administration of a telephone questionnaire.

Throughout the study, all participants will be encouraged to come in for evaluation if they have any concerns. Any data from pregnancy or STI testing at these interim clinic visits will be later collected via chart review. If participants seek reproductive health care at other facilities during the study period, records will be requested with participant permission, and data from pregnancy or STI testing at these outside clinic visits will be collected via review of records received.

We will examine the efficacy of the intervention arm relative to control arm across the following primary behavioral and biologic outcomes over the 12 months of follow-up:

  1. Self-reported dual protection strategy selection
  2. Self-reported dual protection strategy adherence
  3. Incidence of pregnancy or infection with chlamydia, gonorrhea or trichomonas (as confirmed by laboratory testing)

A small pilot study was be conducted prior to the initiation of enrollment in the main study.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

709

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303
        • Grady Health System Teen Services Clinic

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

14 años a 19 años (Niño, Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • female,
  • self-identify as African American,
  • 14-19 years of age,
  • present to clinic on date of potential enrollment for clinical care,
  • has had vaginal sex with a male partner at least once in the past 6 months,
  • HIV-negative by self-report,
  • not currently pregnant (verified by urine pregnancy test),
  • desire to avoid pregnancy for at least 12 months,
  • plan to be in the Atlanta area for the next 12 months,
  • competent to participate in consenting or assenting process per recruiter evaluation,
  • willing to provide contact information, and
  • not previously enrolled in the pilot study of this intervention.

Exclusion Criteria:

  • pregnant
  • HIV positive

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Control
The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
Experimental: Intervention
  1. Enrollment

    • Interactive multimedia platform focused on DP strategies.
    • Intervention arm counseling by a health care provider to select DP strategy.
    • Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.
  2. Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.
  3. 6 month visit

    • Abbreviated version of the interactive multimedia platform on DP strategies and adherence.
    • Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.
  4. Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care.
An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
Otros nombres:
  • MMDP
Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participant selection of an effective dual protection (DP) strategy
Periodo de tiempo: 6 months

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following:

  • Abstinence from vaginal sex;
  • Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use;
  • Consistent condom use only
6 months
Participant report of adherence to DP strategy
Periodo de tiempo: 3 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
3 months
Time to first biologic event (pregnancy or diagnosis with STI) in participants
Periodo de tiempo: Within 12 month period following enrollment
Measured by date of positive lab test ("biologic event" refers to a positive pregnancy test or diagnosis with chlamydia, gonorrhea or trichomonas infection).
Within 12 month period following enrollment
Incidence of pregnancy and sexually transmitted infections (STIs)
Periodo de tiempo: Within 12 month period following enrollment
Includes the proportion of participants with a lab-confirmed diagnosis of pregnancy or lab-confirmed diagnosis with infection with chlamydia, gonorrhea or trichomonas within the 12 month follow-up period (testing either performed at study site clinic and documented at study visits and via chart review, or diagnosed by outside labs with documentation obtained via release of information procedures)
Within 12 month period following enrollment
Participant selection of an effective dual protection (DP) strategy
Periodo de tiempo: 12 months

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following:

  • Abstinence from vaginal sex;
  • Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use;
  • Consistent condom use only
12 months
Participant report of adherence to DP strategy
Periodo de tiempo: 6 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
6 months
Participant report of adherence to DP strategy
Periodo de tiempo: 9 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
9 months
Participant report of adherence to DP strategy
Periodo de tiempo: 12 months

By self-report from audio computer-assisted self-interviewing (ACASI) and telephone questionnaires; adherence is measured by three different outcomes:

  • Whether or not DP strategy was used at last sex
  • Whether or not DP strategy was used consistently during last 3 month time period
  • Estimated proportion of time adherent to DP strategy over last 3 months
12 months
Participant selection of an effective dual protection (DP) strategy
Periodo de tiempo: At enrollment visit

Whether or not a participant self-reports having selected an effective DP strategy. An effective DP strategy is defined as one of the following:

  • Abstinence from vaginal sex;
  • Effective non-barrier contraceptive method [including intrauterine device (IUD), Implant, Depo, or contraceptive pill, patch or ring] with consistent condom use;
  • Consistent condom use only
At enrollment visit

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participant level of reproductive health knowledge (percentage correct of knowledge questions)
Periodo de tiempo: 6 months
Knowledge about contraceptives and STIs, as measured by correct answers to knowledge questions on ACASI questionnaires.
6 months
Participant intention to use DP strategy
Periodo de tiempo: 6 months
Whether or not participant self-reports intention to use an effective DP strategy in the future, as measured by responses on ACASI questionnaires.
6 months
Participant reproductive health self-efficacy
Periodo de tiempo: 6 months
Whether or not participant reported high self-efficacy for condom use, contraceptive use, and communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
6 months
Participant report of STI testing
Periodo de tiempo: 6 months
Frequency of self-reported STI testing by participant and partner(s) and result-sharing with partner(s), as measured by responses to ACASI questionnaires.
6 months
Participant report of partner communication
Periodo de tiempo: 6 months
Self-reported frequency of communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
6 months
Participant level of reproductive health knowledge (percentage correct of knowledge questions)
Periodo de tiempo: 12 months
Knowledge about contraceptives and STIs, as measured by correct answers to knowledge questions on ACASI questionnaires.
12 months
Participant intention to use DP strategy
Periodo de tiempo: 12 months
Whether or not participant self-reports intention to use an effective DP strategy in the future, as measured by responses on ACASI questionnaires.
12 months
Participant report of STI testing
Periodo de tiempo: 12 months
Frequency of self-reported STI testing by participant and partner(s) and result-sharing with partner(s), as measured by responses to ACASI questionnaires.
12 months
Participant reproductive health self-efficacy
Periodo de tiempo: 12 months
Whether or not participant reported high self-efficacy for condom use, contraceptive use, and communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
12 months
Participant report of partner communication
Periodo de tiempo: 12 months
Self-reported frequency of communication with partner on reproductive health topics, as measured by responses on ACASI questionnaires.
12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Melissa Kottke, MD MPH MBA, Emory University; Grady Health System
  • Investigador principal: Jessica Sales, PhD, Emory University
  • Investigador principal: Athena Kourtis, MD PhD MPH, Centers for Disease Control and Prevention
  • Director de estudio: Peggy Goedken, MPH, Emory University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de marzo de 2015

Finalización primaria (Actual)

1 de agosto de 2018

Finalización del estudio (Actual)

1 de agosto de 2018

Fechas de registro del estudio

Enviado por primera vez

24 de julio de 2014

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2014

Publicado por primera vez (Estimar)

14 de noviembre de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de noviembre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

26 de noviembre de 2018

Última verificación

1 de noviembre de 2018

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CDC-NCCDPHP-6588
  • DP12-001 (Otro número de subvención/financiamiento: CDC)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir